ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,0814
-0,02%
Bitcoin
69.253,71
-0,11%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. 2seventy bio Inc (TSVT)

  7. 2seventy bio Inc (TSVT) News

TSVT

2seventy bio (TSVT)

2seventy bio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TSVT
DatumZeitQuelleÜberschriftSymbolFirma
06/06/202401h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
06/06/202401h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
23/05/202413h00Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
17/05/202400h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
09/05/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSVT2seventy bio Inc
08/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
08/05/202413h00Business Wire2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
03/05/202413h00Business Wire2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:TSVT2seventy bio Inc
05/04/202415h05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNASDAQ:TSVT2seventy bio Inc
01/04/202413h30Business Wire2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronNASDAQ:TSVT2seventy bio Inc
20/03/202422h04Business Wire2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsNASDAQ:TSVT2seventy bio Inc
15/03/202423h27Business WireFDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of TherapyNASDAQ:TSVT2seventy bio Inc
07/03/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TSVT2seventy bio Inc
05/03/202413h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
05/03/202413h00Business Wire2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
01/03/202413h00Business Wire2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
05/02/202422h05Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
05/02/202413h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
05/02/202412h59Business WireBristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyNASDAQ:TSVT2seventy bio Inc
02/02/202422h54Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:TSVT2seventy bio Inc
30/01/202415h25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:TSVT2seventy bio Inc
30/01/202413h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
30/01/202413h01Business Wire2seventy bio Announces New Strategic Path ForwardNASDAQ:TSVT2seventy bio Inc
05/01/202422h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSVT2seventy bio Inc
12/12/202313h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
12/12/202301h30Business WireAbecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3NASDAQ:TSVT2seventy bio Inc
11/12/202313h00Business Wire2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)NASDAQ:TSVT2seventy bio Inc
06/12/202320h00Business Wire2seventy bio Reiterates Commitment to Maximizing Shareholder ValueNASDAQ:TSVT2seventy bio Inc
01/12/202312h49Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
01/12/202312h46Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
 Showing the most relevant articles for your search:NASDAQ:TSVT

Kürzlich von Ihnen besucht

TG
TUI1
Tui
AMEX
XLV
Health Care Select Sector
TG
432
Arbor Metals
COIN
BTCUSD
Bitcoin
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MRK
Merck
AMEX
XLF
Financial Select Sector
CCOM
US500
US 500
NASDAQ
GOOGL
Alphabet
TG
RHM
Rheinmetall
CCOM
US100
US Tech 100
AMEX
SPY
SPDR S&P 500
TG
BAYN
Bayer
TG
LHA
Deutsche Lufthansa
NASDAQ
MSFT
Microsoft
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten